echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Novartis Q1: Entresto submits a substitute mine at the end of the year for US$789 million...

    Novartis Q1: Entresto submits a substitute mine at the end of the year for US$789 million...

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 27, Novartis announced the results for the first quarter of 2021.
    Net sales revenue was US$12.
    411 billion (+1%), which was basically the same as last year's first quarter revenue.
    Sales in the Chinese market reached 744 million US dollars, an increase of 11%.

    Novartis' current business is divided into two main lines: innovative drugs and generic drugs.
    In the first quarter, net sales of innovative drugs were US$10.
    1 billion (+4%).
    The generic drug business was mainly responsible for Sandoz.
    Net sales in the quarter were US$2.
    3 billion (-9%).

    From the perspective of specific products, the rheumatoid immune disease treatment drug Cosentyx (skucilumab) and the new heart failure drug Entresto (sacquatril valsartan) contributed a total of 1.
    8 billion US dollars, an increase of 19% year-on-year.
    The CAR-T product Kymriah has grown strongly in all regions, reaching US$151 million (+55%).
    The product coverage continues to expand and has more than 300 qualified CAR-T treatment centers in 28 countries.

    Zolgensma, a gene therapy for spinal muscular atrophy, has benefited from geographical penetration and is currently in an outbreak, with a double-digit growth rate of 88% reaching US$319 million.

    In addition, Novartis mentioned in its financial report the PD-1 tislelizumab introduced from BeiGene on January 12.
    At this year’s AACR meeting, two key clinical results of tislelizumab were announced.
    The median overall survival (mOS) of tislelizumab in the second-line treatment of NSCLC was prolonged by 5.
    3 months more than the second-line treatment of the esophagus.
    The key study of squamous cell carcinoma also reached its primary endpoint.
    Novartis said it will submit a marketing application for these two indications to the FDA before the end of this year.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.